[Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer].
OBJECTIVE
To investigate the influences of PC cell-derived growth factor (PCDGF) and breast cancer resistance protein (BCRP) on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer (NSCLC).


METHODS
Specimens of cancer were collected from 87 chemotherapy-naive patients with advanced NSCLC, 61 males and 26 females, aged 42 - 75. Immunohistochemistry was used to examine the expression of PCDGF and BCRP. After the collection of pathological specimens the patients underwent platinum-based chemotherapy. The relationship between the expression of PCDGF and BCRP and the curative effects of chemotherapy was analyzed.


RESULTS
The overall response rate (OR) to chemotherapy of the 87 patients was 41.38% (36/87), 36 of the patients were chemosensitive (41.38%), and the other 51 were chemoresistant (58.62%). Forty-six of the 87 patients (52.9%) were PCDGF positive, the PCDGF positive rate of the chemoresistant patients was 74.5%, significantly higher than that of the chemosensitive patients (19.4%, P = 0.000). The patients with high PCDGF expression intensity were all chemoresistant. PCDGF expression was significantly associated with response of chemotherapy (P = 0.000). The overall positive BCRP expression rate was 67.82% (59/87). Of the 51 chemoresistant patients 46 were BCRP positive (90.2%), a rate significantly higher than that of the chemosensitive patients (36.1%, P = 0.000). The intensity of BCRP expression was significantly associated with response to chemotherapy (P = 0.000).


CONCLUSIONS
PCDGF and BCRP may be used as biomarkers to predict the first-line response to chemotherapy in patients with advanced NSCLC.
Hu
Yi
Y
Department of Resperatory Diseases, General Hospital of People's Liberation Army, Beijing 100853, China.
Lin
Dong-mei
DM
Cheng
Shu-jun
SJ
Liu
You-ning
YN
Feng
Feng-yi
FY
D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000096:biosynthesis*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009367:Neoplasm Staging; D000077153:Progranulins
C116614:ABCG2 protein, human; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; C492314:GRN protein, human; D036341:Intercellular Signaling Peptides and Proteins; D009363:Neoplasm Proteins; D000077153:Progranulins; D002945:Cisplatin